A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy

Publisher： Karger

E-ISSN： 1662-6575|4|2|260-266

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.4, Iss.2, 2011-05, pp. : 260-266

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4290-4298

John Wiley & Sons Inc

Access to resources Recommend Favorite

Gastroenteropancreatic high‐grade neuroendocrine carcinoma

By  

CANCER, Vol. 120, Iss. 18, 2014-09 ,pp. : 2814-2823

John Wiley & Sons Inc

Access to resources Recommend Favorite

Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 67-71

Karger

Access to resources Recommend Favorite

Severe Organizing Pneumonia after Two Cycles of Docetaxel as Fourth-Line Chemotherapy for Advanced Non-Small Cell Carcinoma of the Lung

By  

Case Reports in Oncology, Vol. 2, Iss. 1, 2009-02 ,pp. : 12-19

Karger

Access to resources Recommend Favorite

Prolonged Clinical Benefit of Everolimus Therapy in the Management of High-Grade Pancreatic Neuroendocrine Carcinoma

By  

Case Reports in Oncology, Vol. 6, Iss. 2, 2013-08 ,pp. : 441-449

Karger

Access to resources Recommend Favorite